How to Buy Cytokinetics Stock
Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Cytokinetics stock last closed at $82.19, up 1.72% from the previous day, and has increased 142.38% in one year. It has overperformed other stocks in the Biotechnology industry by 1.2 percentage points. Cytokinetics stock is currently +151.65% from its 52-week low of $32.66, and -2.79% from its 52-week high of $84.55.
There are currently 124.43M CYTK shares outstanding. The market capitalization of CYTK is $10.23B. In the last 24 hours, 5.86M CYTK shares were traded.
How to Buy Cytokinetics Stock
Not sure how to invest in Cytokinetics stock? Here's how.
- Choose where to buy Cytokinetics stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you determine where to buy Cytokinetics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Choose your method of payment and add your details.
- Research Cytokinetics stock: The Cytokinetics ticker symbol is CYTK. Is Cytokinetics stock a good investment? Should you buy shares of CYTK? How do CYTK's underlying business fundamentals look? Do top analysts think Cytokinetics is a good buy? Why has CYTK's stock price moved recently? (Hint: Our stock analysis website can help you figure out if CYTK is a good stock to buy).
- Place your CYTK trade: Decide if you will purchase CYTK shares at the current market price or use a limit order to purchase CYTK stock at a specific price.
- Keep an eye on your CYTK investment: Create a watchlist to track your position in Cytokinetics stock.
Step 1: Choose where to buy Cytokinetics stock
You need a brokerage account to access the NASDAQ market and buy CYTK shares.
Our recommended brokerage: eToro
Based on our research, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Utilities, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal info so you are able to invest in CYTK stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new trading account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have created your account on the best stock trading app, you need to deposit funds:
Check out the walkthrough below for more details transferring funds into your new investment account.
Step 4: Research Cytokinetics stock
After you have identified the best place to buy Cytokinetics stock, it's important to analyze their stock prior to investing, so you can comprehend the risk and opportunity.
Cytokinetics Numbers
CYTK Due Diligence Score
WallStreetZen was created to help average investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CYTK's stock page.
Is CYTK stock undervalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CYTK's fair value.
You can access more valuation research on CYTK's stock here.
Is CYTK a healthy company?
Passed Financial Due Diligence Checks:
- CYTK has cash burn of 548922000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the CYTK balance sheet.
Failed Financial Due Diligence Checks:
- CYTK profit margin has gone up by 24.18 percentage points in the past year, but the company is still unprofitable.
- Total CYTK debt is still negative.
- CYTK debt to equity ratio of -2.54 is negative.
- CYTK has $818.55M in cash and short term investments. This is not sufficient to cover its annual cash burn of $548.92M.
- There are more long-term liabilities than short-term assets on the CYTK balance sheet.
Is it a good time to buy Cytokinetics stock, according to Wall Street analysts?
Out of 15 sell side analysts who track CYTK, the consensus analyst rating on Cytokinetics is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent CYTK Analyst Forecasts
Yanan Zhu, a top 18% analyst from Wells Fargo maintains CYTK with a strong buy rating and raises their CYTK price target from $95.00 to $105.00, on May 7, 2026.
Wells Fargo's Yanan Zhu raised their price target on Cytokinetics (NASDAQ: CYTK) by 10.5% from $95 to $105 on 2026/05/07. The analyst maintained their Strong Buy rating on the stock.
Cytokinetics reported its Q1 2026 earnings.
Zhu noted that community cardiologists accounted for a disproportionate share of Myqorzo's quarterly sales, demonstrating the benefit of a differentiated risk evaluation and mitigation strategy.
Following the success of ACACIA, the analyst said they (1) anticipate that obstructive hypertrophic cardiomyopathy will continue to gain momentum ,and (2) see synergy with non-obstructive hypertrophic cardiomyopathy.
Earnings Report
For Q1 2026, Cytokinetics reported:
- Loss per share of $1.67, which was in line with the Zacks Consensus Estimate but missed Q1 2025’s $(1.36).
- Revenue of $19.36M, which beat the Zacks Consensus Estimate by 173.34% and Q1 2025’s $1.58M.
Management did not provide EPS and revenue guidance in its press release.
President & CEO Robert I. Blum commented: “The U.S. launch of MYQORZO commenced strongly in late 2026/01 and continues to accelerate.
“We promptly activated a solid prescriber base of early adopters and are encouraged by initial commercial metrics that are exceeding our expectations.
“In addition, today we shared positive topline results from ACACIA-HCM in non-obstructive HCM showing that aficamten improved both symptoms and maximal exercise performance, a milestone achievement that opens the aperture for aficamten to potentially address the entire spectrum of HCM.
“We look forward to building on our strong start and driving meaningful progress for both the commercial launch of MYQORZO and the continued advancement of our pipeline.”
James Condulis, a top 39% analyst from Stifel Nicolaus maintains CYTK with a strong buy rating and raises their CYTK price target from $98.00 to $108.00, on May 6, 2026.
Jeffrey Hung, a top 7% analyst from Morgan Stanley maintains CYTK with a strong buy rating and raises their CYTK price target from $90.00 to $103.00, on May 6, 2026.
Leonid Timashev, a top 4% analyst from RBC Capital maintains CYTK with a buy rating and raises their CYTK price target from $101.00 to $119.00, on May 6, 2026.
Gena Wang, a top 27% analyst from Barclays maintains CYTK with a strong buy rating and raises their CYTK price target from $87.00 to $95.00, on Apr 6, 2026.
You can dive deeper into what analysts are forecasting on the Cytokinetics stock forecast page.
CYTK Trading Indicators
CYTK Earnings
Last year, CYTK revenue was $105.82M. During the last five year, CYTK's revenue has gone up by 12.56% per year. This was slower than the Biotechnology industry average of 32.21%.
You can research CYTK's earnings and revenue performance here.
Are CYTK insiders buying or selling the stock?
Over the last year, insiders at CYTK have sold more shares than they have bought.
Fady Ibraham Malik, EVP Research Development of CYTK, was the latest CYTK insider to buy. They bought $27,300.00 worth of CYTK shares on Jun 23, 2026.
Dig into more about who owns CYTK shares here.
Does CYTK stock generate passive income?
No, Cytokinetics doesn't provide an income stream by paying out dividends.
CYTK Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your CYTK trade
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually sufficient. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a given price limit, use a limit order.
Hit the Open Trade button and eToro will place the order.
If you require additional info about buying stocks on eToro, click the helpful video below:
Step 6: Keep an eye on your CYTK investment
Now that you own some CYTK shares, you'll want to stay up-to-date on your investment.
Create a watchlist to see the latest developments about your CYTK stock.
CYTK Feed
How to Buy Stock in Cytokinetics
To reiterate, here are the 6 steps for buying Cytokinetics stock:
- Choose where to buy Cytokinetics stock
- Open your brokerage account
- Deposit funds into your brokerage account
- Research Cytokinetics stock
- Place your CYTK trade
- Keep an eye on your CYTK investment
If you need a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to keep track of your investment in Cytokinetics, create a watchlist today.
Other Content You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.